Goldman Sachs Predicts Colgate's 2024 Earnings Performance

Written by Emily J. Thompson, Senior Investment Analyst

CL+0.35%

Source: seekingalpha

Updated: 2h ago

0mins

Source: seekingalpha

Earnings Announcement Preview: Colgate-Palmolive is set to release its Q4 earnings on January 30 before market open, with consensus EPS estimated at $0.91 (flat Y/Y) and revenue expected to reach $5.12 billion, reflecting a 3.6% Y/Y growth.
Historical Performance Review: Over the past two years, Colgate has beaten EPS estimates 100% of the time and revenue estimates 88% of the time, indicating a strong track record of financial performance and reliability.
Expectation Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 13 downward revisions, while revenue estimates have experienced 2 upward and 8 downward revisions, highlighting market uncertainty regarding the company's future performance.
Market Analysis Perspective: Despite facing challenges, Colgate-Palmolive is viewed as having a balanced risk/reward profile in 2025, with analysts noting its consistent long-term execution makes it an attractive option in the competitive landscape.

Discover Tomorrow's Bullish Stocks Today

Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.

Sign up now to unlock expert insights and stay one step ahead of the market trends.

CL

$85.3+Infinity%1D

Analyst Views on CL

Wall Street analysts forecast CL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CL is 87.79 USD with a low forecast of 77.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

15 Analyst Rating

10 Buy

4 Hold

1 Sell

Moderate Buy

Current: 85.000

Low

77.00

Averages

87.79

High

95.00

Current: 85.000

Low

77.00

Averages

87.79

High

95.00

JPMorgan

Andrea Teixeira

maintain

$88 -> $93

2026-01-16

Reason

JPMorgan

Andrea Teixeira

Price Target

$88 -> $93

AI Analysis

2026-01-16

maintain

Reason

JPMorgan analyst Andrea Teixeira raised the firm's price target on Colgate-Palmolive to $93 from $88 and keeps an Overweight rating on the shares. The firm adjusted ratings and targets in the beverage, household and personal care products group as part of its Q4 earnings preview. JPMorgan believes the sector setup into earnings remains mixed, with the "most plain vanilla companies" and with those with the most exposure to the U.S. consumer likely to post "lackluster" sales. The stocks exposed to beauty and companies that focus on "differentiated and innovative premium products" should continue to outperform, the analyst tells investors in a research note.

Barclays

Lauren Lieberman

Equal Weight

maintain

$80 -> $83

2026-01-16

Reason

Barclays

Lauren Lieberman

Price Target

$80 -> $83

2026-01-16

maintain

Equal Weight

Reason

Barclays analyst Lauren Lieberman raised the firm's price target on Colgate-Palmolive to $83 from $80 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the consumer staples group as part of a Q4 earnings preview. Barclays attributes the recent "enthusiasm" in the stock to "a flight to safety" and remains concerned about company- and sector-level fundamentals. Potential oil and currency headwinds could materialize in 2026, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CL

Unlock Now

About CL

Colgate-Palmolive Company is a growth company. It is focused on Oral Care, Personal Care, Home Care and Pet Nutrition, it sells its products under brands, such as Colgate, Palmolive, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline and Suavitel, as well as Hill's Science Diet and Hill's Prescription Diet. Its Oral, Personal and Home Care product segment is managed geographically in five segments, such as North America, Latin America, Europe, Asia Pacific and Africa/Eurasia, all of which sell primarily to a variety of traditional and e-commerce retailers, wholesalers, distributors, dentists and skin health professionals. Its Pet Nutrition products include specialty pet nutrition products manufactured and marketed by Hill's Pet Nutrition. The customers for Pet Nutrition products are authorized pet supply retailers, veterinarians and e-commerce retailers.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.